The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy

Erectile Dysfunction Clinical Trial

— DAP-SPEED  

Official title:

The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy in the Treatment of Men With Premature Ejaculation and Erectile Dysfunction (DAP-SPEED Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02939495
• Other study ID #: NEU-16.12
• Secondary ID: 16-NEU-1
• Status: Completed
• Phase: Phase 4
• Start date: October 2016
• Est. completion date: August 2017

Study information

• Verified date: May 2019
• Source: Neutec Ar-Ge San ve Tic A.S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Dapoxetine/Sildenafil 30/50 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.

Description:

During 4-weeks treatment period, patients will take one Dapoxetine/Sildenafil 30/50 mg film coated tablet 1-3 hours before sexual intercourse.

Study drug should not be used more than 1 tablet every 24 hours during the treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: August 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• 18-64 years old men,

• Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study,

• Clinical diagnosis of erectile dysfunction, IIEF score =21,

• Premature Ejaculation Diagnostic Tool (PEDT) score must be =11

• Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) ,

• The patient and his partner must have sexual intercourse twice a week for the duration of the study,

• Commitment to comply with the study protocol,

• Patients who sign informed consent form (ICF).

Exclusion Criteria:

• History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE,

• Having genital abnormalities, except penile curvature unless not prevent sexual intercourse,

• Developed ED or PE due to drug use or quit taking drugs,

• Any conditions that prevent sexual intercourse with partners

• History of epilepsy,

• Severe renal insufficiency,

• Liver disease,

• History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), AV block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angina, life-threatening arrhythmia or hypotension,

• Non-Arteritic Anterior ischemic optic neuropathy,

• Patients who are not eligible to have sexual intercourse due to existing health problems,

• Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled,

• Systolic/Diastolic blood pressure at rest <90/50mmHg and 170/100mmHg<

• History of allergy to Selective Serotonine Reuptake Inhibitor (SSRI) and phosphodiesterase inhibitor drugs,

• Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI), Thioridazine, Serotonine Reuptake Inhibitor (SSRI), Selective-Norepinephrin Reuptake Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and atypical antipsychotic drugs,

• Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine, erithromicin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant, dapoxetine, PDE5 inhibitor, alcohol and stimulant drug,

• Patients on a different therapy (behavioral therapy or other drugs that are applied locally) for PE treatment

• During the study, the possibility of taking medication which may affect the study drug's pharmacokinetic/pharmacodynamic properties

• Patients who are defining symptoms of prostatitis clinically

• Thyroid hormone disorders

Related Conditions & MeSH terms

• Erectile Dysfunction
• Premature Birth
• Premature Ejaculation

Intervention

Drug:
• Dapoxetine/Sildenafil 30/50 mg film coated tablet
1 tablet before sexual intercourse

Locations

Country	Name	City	State
Turkey	Bagcilar Research and Training Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Neutec Ar-Ge San ve Tic A.S

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Tuken M, Culha MG, Serefoglu EC. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study. Int J Impot Res. 2019 Mar;31(2):92-96. doi: 10.1038/ — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline.		4-weeks
Primary	The evaluation of IIEF-15 (International Index of Erectile Function Questionnaire) score compared to baseline.		4-weeks
Primary	The evaluation of premature ejaculation symptom scores compared to baseline.		4-weeks
Secondary	The evaluation of Premature Ejaculation response measured by Premature Ejaculation Profile (PEP)		4-weeks
Secondary	The Rate of Premature Ejaculation Profile (PEP) response		4-weeks
Secondary	The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)		4-weeks